We first screened the inflammatory factors (Inflammatory Factors kits, Roche) in the PBMCs; the level of CCL3 was significantly higher in patients with COPD GOLD 3–4 stage compared with the NS and COPD GOLD 1–2 stage (Figure 1A). This evidence concerns the gene CCL3 and chronic obstructive pulmonary disease.